Children born to women on HIV therapy containing the drug efavirenz were 2 to 2.5 times more likely to have microcephaly, or small head size, compared to children born to women on regimens of other antiretroviral drugs, according to a new analysis. The children with microcephaly also had a higher risk for developmental delays, compared to children with normal head size.
